FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1661-1662 November 30, 2000 Number 22

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

(Respiratory Pharmacology and Pharmacotherapy.) Edited by Mark A. Giembycz and Brian J. O'Connor. 206 pp., illustrated. Boston, Birkhauser, 2000. $219. ISBN 3-7643-5858-0.

In the past two decades, enormous advances in molecular biology and immunology have revolutionized our understanding of disease processes. One disease that is better understood as a result of these advances is asthma. Concepts of the physiological processes of airway narrowing and bronchial hyperresponsiveness have been around for some time, but the integration of this knowledge with immunology has unraveled the mechanisms of these events and led to the understanding that asthma is an inflammatory disease. The delineation of the pathways to inflammation has made it possible to conceive of antiinflammatory mechanisms that explain the effectiveness of existing asthma therapies . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.